Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: murri r. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy.
Gillini LA, Cingolani A, Murri R, De Luca A, Di Giambenedetto S, Wu A, Cauda R, Chaisson RE. Gillini LA, et al. Among authors: murri r. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):546-7. doi: 10.1097/00126334-200204150-00018. J Acquir Immune Defic Syndr. 2002. PMID: 11981374 No abstract available.
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.
De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF, Antinori A. De Luca A, et al. Among authors: murri r. J Infect Dis. 2003 Jun 15;187(12):1934-43. doi: 10.1086/375355. Epub 2003 May 22. J Infect Dis. 2003. PMID: 12792870 Clinical Trial.
Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study.
Murri R, Lepri AC, Phillips AN, Girardi E, Nasti G, Ferrara S, Mura MS, Mussini C, Petrelli E, Arlotti M, De Stefano C, Vigano P, Novati R, Cargnel A, Monforte AD; I.Co.N.A. Study Group. Murri R, et al. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):184-90. doi: 10.1097/00126334-200310010-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14526207
Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance.
Murri R, Ammassari A, Trotta MP, De Luca A, Melzi S, Minardi C, Zaccarelli M, Rellecati P, Santopadre P, Soscia F, Scasso A, Tozzi V, Ciardi M, Orofino GC, Noto P, Monforte Ad, Antinori A, Wu AW; AdICoNa Study Group. Murri R, et al. J Gen Intern Med. 2004 Nov;19(11):1104-10. doi: 10.1111/j.1525-1497.2004.30248.x. J Gen Intern Med. 2004. PMID: 15566439 Free PMC article.
Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients.
d'arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, Grossi P, Galli A, Zauli T, Montroni M, Tundo P, Moroni M; Italian Cohort of Antiretroviral-Naive Patients Study Group. d'arminio Monforte A, et al. Among authors: murri r. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):407-16. doi: 10.1097/01.qai.0000147529.57240.b0. J Acquir Immune Defic Syndr. 2005. PMID: 15764957
Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals.
Trotta MP, Ammassari A, Murri R, Marconi P, Zaccarelli M, Cozzi-Lepri A, Acinapura R, Abrescia N, De Longis P, Tozzi V, Scalzini A, Vullo V, Boumis E, Nasta P, Monforte Ad, Antinori A; AdICoNA and AdeSpall Study Group. Trotta MP, et al. Among authors: murri r. AIDS Patient Care STDS. 2008 Apr;22(4):291-9. doi: 10.1089/apc.2007.0061. AIDS Patient Care STDS. 2008. PMID: 18422461
253 results